Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.354
+0.094 (4.15%)
Nov 21, 2024, 1:34 PM EST - Market open

Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides.

The company’s product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.

Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals logo
Country United States
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Nadav Kidron

Contact Details

Address:
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
United States
Phone 844 967 2633
Website oramed.com

Stock Details

Ticker Symbol ORMP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001176309
CUSIP Number 68403P203
ISIN Number US68403P2039
Employer ID 98-0376008
SIC Code 2834

Key Executives

Name Position
Nadav Kidron Esq. President, Chief Executive Officer and Executive Chairman
Dr. Miriam Kidron Ph.D. Chief Scientific Officer and Director
Avraham Gabay Chief Financial Officer, Treasurer and Secretary
Joshua Hexter Chief Operating and Business Officer

Latest SEC Filings

Date Type Title
Nov 7, 2024 10-Q Quarterly Report
Oct 29, 2024 8-K Current Report
Oct 8, 2024 8-K Current Report
Sep 26, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report
Sep 16, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 14, 2024 10-Q Quarterly Report
Aug 2, 2024 8-K Current Report
Jun 26, 2024 8-K Current Report
Jun 24, 2024 8-K Current Report